SCHEDULE 13G/A: UBS Group AG Files Amended Schedule 13G for Amneal Pharmaceuticals, Disclosing Zero Beneficial Ownership
Beneficial Ownership Disclosure Amendment
UBS Group AG has filed an amended Schedule 13G for Amneal Pharmaceuticals, Inc., reporting zero beneficial ownership of Class A Common Stock as of December 31, 2024, following its acquisition of Credit Suisse Group AG.
Summary
- The document is an Amendment No. 1 to Schedule 13G filed by UBS Group AG regarding its beneficial ownership in Amneal Pharmaceuticals, Inc.
- The issuer is Amneal Pharmaceuticals, Inc., with the securities being Class A Common Stock, par value $0.01 per share (CUSIP 03168L105).
- The reporting person, UBS Group AG, is based in Zurich, Switzerland.
- As of December 31, 2024, UBS Group AG, including its wholly-owned subsidiary UBS Financial Services Inc., beneficially owns 0 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock, representing 0% of the class.
- This filing reflects the ownership status after UBS Group AG acquired Credit Suisse Group AG on June 12, 2023, succeeding to all assets and liabilities of Credit Suisse Group AG.
- UBS Group AG certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amneal Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership (0%) and does not contain positive or negative news regarding the issuer's performance or the reporting entity's investment strategy. It is a neutral compliance filing.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Amneal Pharmaceuticals, Inc. or UBS Group AG's future investment intentions beyond the certification of ordinary course business holdings.
Management Comments
- UBS Group AG certifies that the securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure in the financial services industry, specifically a consequence of the significant merger between UBS Group AG and Credit Suisse Group AG. It clarifies the combined entity's beneficial ownership in a specific pharmaceutical company, Amneal Pharmaceuticals, Inc., indicating no significant stake.
Stakeholder Impact
- Shareholders of Amneal Pharmaceuticals, Inc. are informed that UBS Group AG does not hold a significant beneficial ownership stake in the company.
- For UBS Group AG shareholders, this is a routine compliance filing related to the integration of Credit Suisse Group AG.
Key Dates
| Date | Description |
|---|---|
| 06/12/2023 | UBS Group AG acquired Credit Suisse Group AG. |
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 02/10/2025 | Date of filing/signature of the Schedule 13G Amendment No. 1. |
Keywords
Amneal Pharmaceuticals, UBS Group AG, Schedule 13G, Beneficial Ownership, SEC Filing, Class A Common Stock, Credit Suisse Acquisition, Financial Services
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.